Literature DB >> 17454345

Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington's disease.

Maree Farrow1, Andrew Churchyard, Phyllis Chua, John L Bradshaw, Edmond Chiu, Nellie Georgiou-Karistianis.   

Abstract

Research in preclinical mutation carriers for Huntington's disease (HD) aims to find measures sensitive to preclinical decline. This study investigated attentional abilities in mutation carriers and noncarriers. Mutation carriers demonstrated a normal "attentional blink" during rapid serial visual presentation, normal covert visual orienting, and normal directing of attention to tactile stimuli. However, they were more likely than noncarriers to make anticipatory responses before target presentation. Additionally, those closer to estimated onset of HD demonstrated larger "inhibition of return" effects. The findings suggest potential changes in cognitive inhibition of unwanted responses, and in automatic inhibition of visual orienting, in preclinical HD.

Entities:  

Mesh:

Year:  2007        PMID: 17454345     DOI: 10.1080/13803390600657693

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  4 in total

1.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

2.  The effect of interference on temporal order memory in premanifest and manifest Huntington's disease.

Authors:  Diane R Nicoll; Eva Pirogovsky; Adrienne E Collazo; Savanna M Tierney; Jody Corey-Bloom; Paul E Gilbert
Journal:  J Huntingtons Dis       Date:  2013

3.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

4.  Neuropsychological deficits in Huntington's disease gene carriers and correlates of early "conversion".

Authors:  Jason Brandt; Anjeli B Inscore; Julianna Ward; Barnett Shpritz; Adam Rosenblatt; Russell L Margolis; Christopher A Ross
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2008       Impact factor: 2.198

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.